Hereditary BRCA1 or BRCA2 germline mutations have been identified in 5% to 10% of epithelial ovarian cancers (9, 10), although tumor development in these individuals requires somatic inactivation of the remaining wild-type (WT) allele (11). Here, BRCA2 is linked to neoplasm.